Gavreto (Pralsetinib)

Brand Name

Gavreto

Generic Name

Pralsetinib

View Brand Information

FDA approval date: July 01, 2021

Classification: Kinase Inhibitor

Form: Capsule

What is Gavreto (Pralsetinib)?

GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by an FDA approved test .

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer

Who is this study for: Patients with locally advanced, unresectable, stage III non-small cell lung cancer

Enrollment Status: Recruiting

Publish Date: October 02, 2025

Intervention Type: Drug

Study Drugs: Alectinib, Entrectinib, Pralsetinib, Durvalumab

Study Phase: Phase 3

Summary: This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Enrollment Status: Recruiting

Publish Date: September 22, 2025

Intervention Type: Drug

Study Phase: Phase 2

Summary: TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high...

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Enrollment Status: Recruiting

Publish Date: August 14, 2025

Intervention Type: Drug

Study Phase: Phase 4

Summary: This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion cri...

View All Clinical Trials

Related Latest Advances

Corneal edema and epithelial defect during pralsetinib treatment.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 29, 2025

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2025

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: June 03, 2025

View All Latest Advances

Brand Information

Gavreto (Pralsetinib)

1DOSAGE FORMS AND STRENGTHS

Capsules: 100 mg, light blue, opaque, hard hydroxypropyl methylcellulose (HPMC) capsule printed with "BLU-667" on the capsule shell body and "100 mg" on the capsule shell cap.

2CONTRAINDICATIONS

None.

3ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

Interstitial Lung Disease/Pneumonitis
Hypertension
Hepatotoxicity
Hemorrhagic Events
Tumor Lysis Syndrome
Risk of Impaired Wound Healing
Embryo-Fetal Toxicity

3.1Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population in the WARNINGS AND PRECAUTIONS reflect exposure to GAVRETO as a single agent at 400 mg orally once daily in 540 patients in ARROW

4DESCRIPTION

Pralsetinib is an oral receptor tyrosine kinase inhibitor. The chemical name for pralsetinib is (

The solubility of pralsetinib in aqueous media decreases over the range pH 1.99 to pH 7.64 from 0.880 mg/mL to < 0.001 mg/mL, indicating a decrease in solubility with increasing pH.

GAVRETO (pralsetinib) is supplied for oral use as immediate release hydroxypropyl methylcellulose (HPMC) hard capsules containing 100 mg pralsetinib. The capsules also contain inactive ingredients:

citric acid, hydroxypropyl methylcellulose (HPMC), magnesium stearate, microcrystalline cellulose (MCC), pregelatinized starch and sodium bicarbonate. The capsule shell consists of FD&C Blue #1 (Brilliant Blue FCF), hypromellose and titanium dioxide. The white printing ink contains butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, strong ammonia solution and titanium dioxide.

5HOW SUPPLIED/STORAGE AND HANDLING

GAVRETO (pralsetinib) 100 mg, light blue, opaque, immediate release, hydroxypropyl methylcellulose (HPMC) hard capsule printed with "BLU-667" on the capsule shell body and "100 mg" on the capsule shell cap are supplied as follows:

Bottles of 60 capsules (NDC 71332-006-60).
Bottles of 90 capsules (NDC 71332-006-90).
Bottles of 120 capsules (NDC 71332-006-12).

6PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

7PRINCIPAL DISPLAY PANEL - 60 Capsule - Carton

NDC 71332-006-60

GAVRETO^®
(pralsetinib)
capsules

100 mg

For Oral Use

Rx only

60 Capsules

rigel

8PRINCIPAL DISPLAY PANEL - 90 Capsule - Carton

NDC 71332-006-90

GAVRETO^®
(pralsetinib)
capsules

100 mg

For Oral Use

Rx only

90 Capsules

rigel